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Missed minority drug resistance mutations (DRMs) may pave a way to therapy failure in a short 
period of time. Therefore, the use of sensitive assays to monitor the presence of minority DRMs in 
HIV-1 infected individuals especially children is important and urgently needed for better patient 
management. Assays have been developed including next generation sequencing (NGS) that are able 
to identify a larger proportion of quasi-species including those bearing minority DRMs within a 
patient's viral population. This intervention is crucial particularly among children who would require 
antiretroviral therapy (ART) for their lifetime. Therefore, the aims of this study was to (1) describe the 
prevalence of minority HIV quasi-species harbouring DRMs in paediatric patients at virologic failure 
in a rural KwaZulu-Natal (KZN) paediatric cohort using NGS technology and (2) to compare the 
genotypes generated using Sanger sequencing with NGS. 
 
Study design 
This retrospective study was conducted on archived samples (n= 34) collected from August 2011 to 
June 2014 from infants and children ≤15 years of age on first-line ART (13 on PI-based regimen and 
21 on an NNRTI-based regimen) and experiencing virologic failure (defined as two successive viral 
load results >1000 copies/ml) from a rural KwaZulu-Natal cohort.  
 
Methods 
Thirty four patients were genotyped using both Sanger sequencing and NGS. A 1.3kb region of the Pol 
gene was genotyped using Sanger sequencing, while the whole 9.7kb HIV genome was sequenced 
using NGS.  All electropherograms were analysed using the Geneious V8.0.5 software system for the 
presence of drug resistance mutations including minority drug resistance mutations. Sequences were 
assembled against an HIV-1 subtype C reference sequence from South Africa. For NGS a reference 
sequence was annotated with known HIV resistance mutations within the protease and RT genes. Drug 
resistance mutations were identified using the RegaDB which references the Stanford, Rega and 
ANRS resistance algorithms and analysed in correlation with selected clinical and demographic data 
in STATA v11. 
 
Results 
NGS was able to detect minority DRMs in eleven (32.3%) samples which were missed by Sanger 
sequencing. NGS also detected an additional three (8.8%) specimens that harboured DRMs but were 
found to be susceptible by Sanger sequencing. Patients on PI-based regimen had a lower prevalence of 
mutations compared to those on an NNRTI=based regimen. 
 
Conclusion 
The presence of minority DRMs among paediatric patients is likely to obstruct the use of ART and 
consequently predispose patients to therapy failure.  This emphasises the critical importance of using 
specific and sensitive assays for the detection of minority DRM early in treatment particularly among 
children. We noted that children on PI-based regimen, while at a lower prevalence still harboured 
DRMs that remained undetected by conventional Sanger sequencing.  Finally, this study emphasised 
the need to apply more sensitive assays to accurately distinguish patients failing due to the emergence 
of minority DRMs from those that are non-adherent in order to maximize the efficacy of the limited 




The human immunodeficiency virus type 1 (HIV-1) subtype C accounts for the majority of HIV-1 
infections in the world with the Sub-Saharan African region bearing the highest burden 
1
. Globally, it 
was estimated that in 2014 the number of children ( ≤15 years) living with HIV-1 was approximately 
3.2 million
1, 2
, 2.9 million (91%) of which were from Sub-Saharan region alone
3
. The Republic of 
South Africa has the largest HIV-1 epidemic in the world with approximately 7 million people living 
with HIV which 240 000 infected individuals are children ≤15 years of age
2, 4
. The KwaZulu-Natal 
province of South Africa has one of the highest prevalence  rates  bearing  35.9% of this South African 
epidemic 
2, 4
. Mother to child transmission (MTCT) accounts for the majority of HIV-1 infection in 
children from resource-limited settings including South Africa
5, 6
. However, the use of ART has shown 
to effectively  children
5
. In the absence of  ART up to 50% of children will die from infection before 
they even reach the age of two
7
. It was reported that by the end of 2014, HIV-1 infections among 
children was reduced by 58% from 520 000 in year 2000 down to 220 000 in 2014 globally
2
. 
However, the rate of ART coverage in children still lags behind that of adults
2, 8
, despite Sub-Saharan 
region bearing equal HIV-1 disease burdens among children and adults (Fig. 4)
9
. By 2014 only 32% of 
infected children had access to ART world-wide
2
, but the use of  the antiretroviral (ARV) prophylaxis 
nevirapine (NVP) either as a single dose intervention at birth or an extended treatment option into 
infancy has resulted reduction of  HIV-1 infection rates  in children and preventing HIV transmission 




In 2004, South Africa initiated ART rollout to HIV-1 infected individuals including children.  
According to South African ART recent guidelines all children <1year irrespective of CD4 cell count 
should start ART immediately based on WHO Clinical Stage 4 or at a CD4 count of <200 cells/µl or 
15%. Older children between 5 and 15 years of age should start based on WHO  Clinical Stage 3 or 4 
or at a CD4 count of <500 cells/µl (Table 1)
6
.There has since been a rapid increase in ART access 
making it the world’s largest ART programme yet
4
. Despite these gains, patients might experience 
treatment failure defined as two successive viral load results >1000 copies/ml following at least one 
year on ART
4, 11
.  Reasons for treatment failure among children include:(1) inadequate dosing, (2) 
poor adherence, (3) long-term challenges due to  the limited number of approved ARTs with paediatric 
friendly formulations, (4) limited laboratory infrastructure to monitor treatment efficacy and (5) the 
almost inevitable emergence of drug resistance mutation (DRM)
12
. In a resource-limited setting such 
challenges severely inhibit the benefits of an effective ART programmes among patients, representing 
a serious public health problem especially dreadful among children. Given the greater overall duration 
of ART exposure in infants and children, there is an urgent need to minimise these challenges in order 

















Table 1: Standardised national eligibility criteria for starting ART regimens for Infants and children
6
 
Eligible to Start ART 
 All children < 5 years, irrespective of CD4 
  
Children 5 – 15 years: WHO clinical stage 3 or 4 OR CD4 ≤ 500 cells/µL 
 
 
Require Fast-Track (i.e. start ART within 7 days of being eligible)  
 
 Children less than 1 year of age  
 WHO clinical Stage 4  
 MDR or XDR-TB  
 CD4 Count < 200 cells/μl Or < 15%  
 
To date, the emergence of HIV-1 DRMs remains the most important factor that contributes to 
treatment failure in patients on highly active antiretroviral therapy (HAART)
12
. In general ART will 
prevent the emergence of DRMs and it would be unlikely that a patient will have a virus that is 
resistant to two or more drugs with different mechanism of action
13
,  provided the patient is fully 
adherent to their regimen. Due to the absence or very low proofreading activity of DNA-dependant 
RNA polymerase, the HIV-1 replication cycle is characterised by a high mutation rate with an average 
of 10^4 substitution per nucleotide copied
14
 resulting in a complex population of diverse particles that 
contain closely related but not identical genomes termed viral quasi-species or minority variants
14
. As 
a result, HIV-1 infected patients will have a diverse range of minority variants that may obstruct the 
effectiveness of ART in cases of sub-optimal ART because a regimen in use will be insufficient to 
stop viral replication
13, 15
. Among children minority DRMs could occur as a result of mother-to-child 





Therefore, WHO recommends that in the process of scaling up ART developing countries should 
establish a national surveillance program for HIV drug resistance monitoring
4
. This includes 
genotyping at baseline to detect resistance mutations to be performed for all HIV-1 infected infants 
who have been exposed to any form of ART taken by the mother or infant for prevention of mother to 
child transmission (pMTCT) of HIV
4, 17
. In South Africa ARV drug resistance testing guidelines 
recommend drug resistance genotyping for all patients (children and adults) experiencing virologic 
failure
4
 after adherence and other psycho-social issues have been addressed 
17
. In a resource-limited 
setting such as South Africa where sdNVP was widely employed in pMTCT programmes, nevirapine 
(NVP) associated DRMs are expected and common
6
. This poses an obstacle in countries where NVP 
is a major component in first-line ARV regimens
6
; for example, Y181C will persist for longer periods 
occurring as minority DRMs resulting in therapy failure
15
. However , by 2015 WHO released new 
guidelines recommending lifelong ART for all pregnant and breastfeeding women living with HIV
6
. 
Where lifelong ART is provided to all pregnant and breastfeeding women living with HIV regardless 









Treatment should be maintained after delivery and completion of breastfeeding for life. Of equal 
importance is an early identification of patients on a failing regimen due to poor adherence as opposed 
to drug resistance
18
, because once on HAART poor adherence is also strongly related to therapy 
failure
19
. A standard population sequencing method is currently used for resistance genotyping
4, 15, 20, 
21
; however, this method is only sensitive if DRMs are occurring at a frequency of >20% within the 
total patient's viral population
15, 20, 21
. As a result this assay will miss minority DRMs occurring at 
frequencies < 20%. However, minority DRMs occurring at < 20% frequency within the patient’s viral 
population are also important to understand
11, 16, 18, 20, 22
, whether their presence has any clinical 
implications remains a point of debate but evidence is emerging that they could result in considerable 
implications to therapy failure. Therefore, minority DRMs are important to understand
11, 16, 18, 20, 22 
, 
studies have shown that the presence of baseline
22
,  pre-treated minority DRMs acquired during 
pMTCT
9, 15, 23
 or during ART was correlated with the virologic failure on subsequent future NNRTI-
based regimen. There is strong evidence of the correlation between pre-existing minorities DRMs to 
DRMs detected at virologic failure. The question remains could the presence of minority DRMs be 
used as a marker to predict future virologic failure? 
 
A number of studies have established that DRMs occurring at frequencies of <20% of the total viral 
population (minority DRMs) will complicate the benefits of current and future ART options
11, 16, 18, 20, 
22, 24
. Resource-limited settings such as South Africa follow the public health approach to ART 
delivery with standardised regimens containing limited first-line and second-line options available for 
HIV-infected individuals
12
. Two nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-
nucleoside reverse transcriptase inhibitor (NNRTI)  or two NRTIs plus a protease inhibitor (PI) drug
6
. 
The  emergence of DRMs on first-line therapy compromises second-line therapy success
13
. However, 
Hosseinipour et al 2013 reported that drug resistance patterns detected early at the time of first-line 
failure on an NNRTI-based regimen could be predictable and have a low risk of compromising 
second-line PI-based regimen options if these DRM patterns are identified early after virologic failure 
or ≤12 months after initiating ART
25
. Given that, resource-limited countries including South Africa 
have limited ART options available for HIV-1 infected patients
12
. The presence of DRMs including 
minority DRMs is of the great concern and severely limits ART options as well as future ART 
successes 
7
. ART has proven successful at reducing the burden of the HIV/AIDS epidemic
10
, by 
decreasing the number of  AIDS-related deaths by 36.7% by 2014 among children and new HIV 
infections by 58% among children
2
.  A direct result is effectively prolonged lives spans where HIV-
infected infants are now surviving to adolescence and even adulthood
17
.   
 
Sensitive assays have been developed including next generation sequencing (NGS) and ultra-sensitive 
real-time polymerase chain reaction (qPCR) that are able to identify a larger proportion of quasi-




. This is due 
to their abilities to detect variants at frequencies as low as ≤1%. Hunt et al 2011 noted from 255 South 
African infants previously exposed to NVP that Sanger sequencing missed a number of mutations 
detected using a sensitive allele-specific PCR (ASPCR) assay
15
. While Vignoles et al 2009, 
demonstrated the importance of using a sensitive assay in a cohort of newly diagnosed vertically 
infected ART-naive children (n=35) from Argentina. Using population genotyping they found that 
63(6% ) of the children had M184V mutation; however, when a sensitive qPCR method was used an 
additional 45.5% of the children harboured DRMs associated with therapy failure
22
. Similarly Rowley 
et al 2010 conducted a study in patients from Botswana  and detected minority variant with K103N 










Given that, while the use of minority in treatment monitoring and surveillance remains a point of 
contention given that threshold for clinical revelerance remains unclear. There is nonetheless the 
possibility that ultra-sensitive DRM detection assay may be used to assess the likelihood of therapy 
failure in short period of time
14
. The use of sensitive assays to monitor the presence and the prevalence 
of minority DRMs in HIV-1 infected individuals especially children is crucial and urgently needed. 
Such cases may result in patients being maintained on a failing regimen for a long period of time 
(months to years) that leads to a high prevalence of DRMs complex resistance patterns including 
cross-resistance to multiple drugs within a class or over drug classes and accumulation of thymidine 
analogue mutations (TAMs)
19
. As a result, long standing virologic failure may compromise the 
potency of the components  within future ART regimens
19
. Equally disturbing is the accumulation of 
TAMs which results in diminished susceptibility to multiple nucleoside reverse transcriptase inhibitors 
(NRTI) thus causing broad cross-resistance to the NRTI drug class
19, 26
. This study aims to investigate 
the prevalence of minority HIV quasi-species harbouring DRMs in paediatric patients at virologic 
failure in rural KwaZulu-Natal (KZN) cohort. By using NGS platform parallel with standard Sanger 
sequencing method in children from a decentralized rural public health setting we also contrast the 
frequency of drug resistance mutations detected by either method. 
 
1.2 Justification 
South Africa is one of the countries that is heavily struck by HIV-1/AIDS
2, 4, 27
. By 2014, the use of 
ART among infected  children has shown to effectively reduce new infections by 52% and mortality 
rates by 50%
10
. However, the emergence of DRMs is inevitable and remains a major setback for ART 
successes
12
. Among children this is of increasing concern representing a  hindrance to the achievement 
of long-term ART in South Africa
28
 and of maximising ART benefits given that South Africa is 
having limited options. As well as the presence of minority DRMs, since several studies have reported 
that the presence of these DRMs in infected individuals could result in virologic failure within the first 
year on ART. All of these studies were conducted from an urban area, no investigation to our 
knowledge have been conducted in a rural setting (Table 2). However, ART outcomes in children 


























Table 2: Summary of studies conducted on children at virologic failure harbouring HIV minority drug-
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Therefore, the detection and monitoring of HIV drug resistance mutations are important to ensure 
continuous ART efficacy
4
. In resource-limited settings due to limited ART options, infrastructure and 
data to guide decision making children may remain in virologic failure for longer periods resulting in 
high prevalence of DRMs and cross-resistance that severely limit future ART options
13
. A study 
conducted in infants from Johannesburg, South Africa reported that a decision to switch children from 
an expensive PI to NNRTI-based regimens was based on the detection  and  prevalence of DRMs 
15
. 
We found studies conducted in children initiated on PI-based regimen stating that, while on virologic 
failure the presence of DRMs was very low to none. The identification of DRMs in patients at 
virologic failure could be a tool for distinguishing patients failing due to resistance mutations from 
those that are non-adherent. By doing so, unnecessary switches will be avoided, maximising the ART 
17 
 
regimens still available. In general 40% of adults patients will re-suppress HIV without regimen 
switch
19
. However, given the complexity and severity of paediatric disease, achieving this goal is 
likely to be challenging in children. 
 
In South Africa drug resistance monitoring is not used routinely to manage patients on ART, probably 
due to the high cost of genotyping and limited facilities to perform such tests. However, there is a need 
for interventions that focus on the prevention and monitoring of HIV-1 drug resistance including 
correct identification of minority variants harbouring DRMs using cost effective sensitive assay. As a 
result a number of sensitive assays such as NGS have been developed which are able to detect 
minority variants occurring at frequencies down to <1% within an entire viral population
15
. NGS 
assays provide accurate and sensitive HIV drug resistance detection to minority variant levels in a high 
throughput manner. In addition; it provides the capacity to scan the entire HIV genome for the 
presence of DRMs in a single run. These features provide distinct advantages over Sanger sequencing 
that detects only anticipated mutations. Therefore, the aim of this study is to investigate the prevalence 
of minority HIV-1 DRMs in infected infants and children at virologic failure in a rural Kwa-Zulu 
Natal cohort using both Sanger sequencing and NGS. To the ability of NGS and Sanger sequencing to 
detect and quantify the prevalence of minority HIV quasi-species harbouring DRMs from this rural 
KZN cohort. 
 
1.3 Aims of the study 
1. To investigate the prevalence of minority HIV quasi-species harbouring DRMs in paediatric patients 
at virologic failure in rural KwaZulu-Natal (KZN) cohort. 
 
2. To assess how many additional mutations are detected by NGS when compared to Sanger sequencing. 
 
1.4 Objectives 
1. To assess the efficacy and application of NGS platform as a sensitive assay for minority DRMs 
identification thus, distinguishing non-adherent patients from those harboring resistance mutations 
among infants and children at first-line virologic failure. 
 
2. To determine the prevalence of minority HIV DRMs in children and compare the prevalence and 
patterns of DRMs detected by Sanger sequencing versus NGS.  
 
 
3. To  compare the prevalence of minority DRMs among patients on PI-based regimens versus those on 





2. Literature Review 
2.1 Human Immunodeficiency Virus-1 
HIV-1 (Fig. 1) is an RNA virus that belongs to genus Lentivirus a family of Retroviridae. Lentiviruses 
are classified as slow viruses which infect many species characterized by long-term illnesses and 
incubation periods 
32
. HIV is divided into two types HIV-1 and HIV-2 with HIV-1 being the most 
common type
33
. HIV is the cause of the acquired immunodeficiency syndrome (AIDS) which is a 
slowly progressive and degenerative disease of the human immune system
34
. Globally, in 2013, 
approximately 35 million were living with HIV-1 virus. Briefly, HIV-1 contains nine open reading 
frames namely: Gag, Pol, Env, Tat, Rev, Nef, Vif, Vpu and Vpr that produce 15 proteins
35
. These 
products are divided into three major categories; the Gag polyprotein precursor is proteolytically 
processed to generate the matrix (MA), capsid (CA), nucleocapsid (NC) and p6 proteins. While Gag-
Pol polyprotein contains protease (PR), reverse transcriptase (RT) and intergrase (IN)
36
, and lastly env 
gene that encodes for 30-amino-acid, signal peptide (SP), gp120 and gp41.They are transmitted as a 


















2.1.1 Genetic variability  
HIV is sub-divided into three distinctive lineages: namely the major group M, the outlier group O and 
the two new groups N (non-M, non-O) and P
37
. Group M is sub-divided into nine subtypes designated 
by letters A, B, C, D, F, G, H, J and K 
38
. The dominant viral forms are subtypes A and C followed by 
subtype B; the dominant recombinants are CRF01-AE and CRF02-AG. The dominant viral form in 
South Africa is subtypes C.  The great genetic diversity of HIV-1 has been found in Africa caused by 




2.1.2 HIV life cycle 
HIV virions enter the human cell by attaching its viral membrane glycoprotein to CD4 receptors and 
CCR5 or CXCR4 co-receptors of the target cell. Once within the cell, the viral RNA genome is 
reverse transcribed into a full length double stranded DNA through an error-prone enzyme called 
reverse transcriptase (Fig. 2). Pro-viral DNA is then integrated into the host chromosome by the 
integrase enzyme. Whilst in the cell, pro-viral DNA can either  enter a latent state or actively replicate 
to form a large number of virus particles that are then released to infect neighbouring cells
39
. New 
viral RNA is then translated into precursor protein gp160 which is glycosylated within the 
endoplasmic reticulum. Gag-pol gene is primarily translated to produce the Gag and Gag-Pol 
polyprotein; a precursor that is proteolytically processed during the maturation of the virus into six 










































2.2 Antiretroviral Drugs (ARVs) 
Despite the substantial number of ARVs developed over the past 30 years, since the discovery of HIV. 
HIV-1 remains incurable and only treatable as a chronic disease
41
. The primary goal of ARVs is to 
reduce HIV-related morbidity and mortality by hindering HIV replication
42
. ARVs mode of action is 
by interfering with critical steps of the viral life-cycle namely: adsorption, entry, fusion, un-coating, 
reverse transcription, integration, transcription and maturation. In recent years newer compounds have 
been developed including those that target viral entry (CXCR4 and CCR5 antagonists) and virus-cell 
adsorption/fusion compounds by interacting with either gp120 or gp41 
43
. Consequently, ARVs are 
classified on the basis of the target with which they interact during HIV-1 replication 
44
 .  
 
The first HIV-1 specific antiviral drugs were administered as mono-therapy in the early 1990s
45
. 
However, highly active antiretroviral therapy (HAART) mainly used in South Africa involves a 
combination of two or three anti-HIV-1 drug classes (NRTI, NNRTI, PI) is effective in suppressing 
HIV-1 replication
46
. The principle of HAART is to act at the different viral targets to achieve the 
highest possible benefit, tolerability and compliance and to reduce the risk of resistance 
development
44
.   
 
2.3 Mechanisms action for ARVs 
2.3.1 Nucleoside reverses transcriptase inhibitors (NRTIs)  
NRTIs were the first class of drugs to be approved by FDA
45
, and forms the backbone of ARV 
regimens in resource-limited settings including South Africa. Currently, there are six FDA-approved 
NRTIs (nucleoside and nucleotides reverse transcriptase inhibitors) currently available in South Africa 
for infants and children, namely: Abacavir (ABC), Didanosine (ddI), Lamivudine (3TC), Stavudine 
(d4T), and Zidovudine (AZT). The nucleotide reverses transcriptase inhibitors Tenofovir (TDF) 




2.3.2 Non-nucleoside reverses transcriptase inhibitors (NNRTIs)  
The NNRTI class of drugs form one of the bases for ARV regimens
47
. NNRTIs block HIV-1 
replication by binding distal to the active site of the RT
48
 thereby blocking the binding pocket and 
interfering with the normal functioning of the RT (Fig. 3)
44
. Since 2004, there are four FDA-approved 
NNRTIs available in South Africa namely: Efavirenz (EFV) and NVP Etravirine (ETR) and 
Rilpivirine (RPV)









2.3.3 Protease inhibitors (PIs)  
PIs prevent the cleavage of the gag and gag-pol precursor polyproteins to the structural proteins (p17, 
p24, p7, p6, p2, p1) and functional proteins (protease, RT/RNase-H and integrase), thus arresting 
maturation and thereby blocking infectivity of the newly synthesised virions (Fig. 3)
43
. PIs presently 
available for the treatment of HIV infections in South Africa for children include Lopinavir boosted 
with ritonavir (LPV/r)
45 and Darunavir (DRV)6. 
 
2.3.4 Entry inhibitors 
Entry inhibitors can be subdivided into two distinct classes based on their mode of action namely: 
fusion inhibitors (FI) and small-molecule CCR5 antagonists
45
. FIs form a complex group of ARVs 
with multiple mechanisms of action depending on the stage of the viral entry process they target. Two 
entry inhibitors currently approved are enfuvirtide and maraviroc. Enfuvirtide disrupts conformational 
changes in gp41 that drive membrane fusion,whereas Maraviroc a CCR5 antagonist blocks 




2.3.5 Integrase inhibitors (II)   
Retrovirus integration requires at least two viral components: namely the integrase enzyme, and cis-
acting sequences at the retroviral DNA termini U3 and U5 ends of the LTRs
43
. IIs interact with the two 
essential magnesium metal ion cofactors in the integrase active site of the  viral DNA
45
. As a result, IIs 
block the integration step of viral DNA into the host chromosome, preventing the production of the 




2.4 Antiretroviral Therapy (ART) 
The use of ART has changed from mono-therapy in 1990’s to combined ART known as HAART in 
1996. Since then, HAART has been used to treat HIV-1 infected patients in developed countries
51
. By 
late 2003 South Africa launched their ART scale-up program which started to run in April 2004. By 
2013, 12.9 million people were receiving ART. As a result, the number of people dying of HIV/AIDS 
has declined by 41% which is 100 000 fewer deaths in 2013
27
. The South African Department of 





Despite an extensive  rate of ART scale-up  program in South Africa, the coverage of children still 
lags behind  that of adults (Fig. 4)
8
. Three of four children living with HIV-1 are not receiving ART. 
 





< 3 years or older children weighing < 10kg  ABC + 3TC + LPV/r  
 
> 3 years and > 10kg ABC + 3TC + EFV  
 
 
Currently on d4T-based regimen  
 
Change d4T to ABC if viral load (VL) is 
undetectable (< 50 copies/mL) If VL > 1000 
copies/mL: Manage as possible treatment failure 
If VL 50 – 1000 copies/mL: Consult with expert 
or phone the HIV hotline 
Adolescents > 15 years AND > 40 kg and CrCl > 
80mL/min 
TDF + FTC (or 3TC) + EFV Provided as fixed 
dose combination (FDC) 
Currently on ddI containing regimen Change ddI to ABC, regardless of VL 
Second-line Regimen 
Failed first-line Protease Inhibitor (PI) based regimen 
 
Failed first line PI-based regimen Action 
 
ABC + 3TC + LPV/r  
d4T + 3TC + LPV/r  
Unboosted PI-based regimen, while taking 
rifampicin 
Consult with expert for advice and consider 
resistance testing in patients on LPV/r > 12 
months and adherent to treatment 
 
 
Failed First-line NNRTI-based regimen (discuss with expert before changing) 
 
 




ABC + 3TC + EFV (or NVP) AZT + 3TC + LPV/r 
d4T + 3TC + EFV (or NVP) AZT + ABC + LPV/r 
Third-Line Regimen 
Failing any 2nd line regimen  
 
Should be managed by a Paediatric Infectious 
Disease Specialist on the basis of genotype 
resistance testing. Access to third line ART is 
managed centrally by the National Department of 
Health 
Note: Children ≥ 3 years and exposed to NVP for 6 weeks or longer (PMTCT) should be initiated on   









Figure 4: Number of children eligible for, and receiving antiretroviral therapy in low and middle-




2.4.1 ART in children 
Access to ART for children has improved over years. By late 2003 South Africa launched their ART 
scale-up program which started to run in April 2004. Since then the number of children dying from 
HIV/AIDS has declined by 50% 
27
.  South African eligibility criteria state that all children less than 5 
years irrespective of CD4 should start ART immediately, whereas older children between 5 and 15 
years of age should start based on their WHO clinical stage 3 or 4 or CD4 <350 cells/µl
6
. Eleven years 
later ART options are still limited in South Africa and even fewer options for infants and children 
52
. 
In a South African public sector a  number of 9 ARV are available for paediatrics ART offered as  

















2.5 HIV drug resistance 
As the ART coverage continues to grow in Sub-Saharan Africa, some degree of drug resistance 
development will be inevitable
54
. The development of drug resistance in HIV-1 infected patients is due 
to the production of genetic variation in the virus due to the selection of drug-resistant pressure during 
ART. Studies have shown that a major cause of therapy failure in HIV-infected patients is generally 
associated with the development of HIV DRMs
55
. The Sub-Saharan Africa region has large numbers 
of HIV-infected individuals in need of life-long ART. However, this region has the limited ART 
options. Therefore, it is crucial that available regimens are used effectively and to their maximum 




The emergence of HIV-1 drug resistance should be distinguished from other causes of therapy failure 
such as non-adherence, insufficient drug levels and drug regimens with intrinsically weak antiviral 
activity 
56
. To date the ways of making this distinction include adherence counselling, resistance 
genotyping or measurement of drug levels
17
. These methods may be unreliable, costly and 
inaccessible, particularly in resource-limited settings. Barriers to adherence namely: regimen 
complexity, side effects, patient related factors in HAART adherence, psycho-social issues, belief 
systems and the patient-provider relationship may all result  to the development of drug resistance
57
. 
The emergence of drug resistance should be monitored so that required interventions should be taken 




HIV-1 genotypic variants carrying viral protease or RT resistance conferring mutations to one or more 
ARV drugs can be classified into primary or secondary mutations
56
. Primary (transmitted) drug 
resistance  occurs when a person is infected with a strain of HIV that is resistant to ARV drugs
58
. 
Secondary (acquired) resistance develops over time
58
 and is due to the accumulation of resistance 
mutations that allow the virus to persist despite the selective pressures exerted by HAART resulting in 
therapy failure
14
. The  mutations in the HIV genome that confers drug resistance can limit the use of 




2.5.1 Drug resistance in children 
The development of DRMs in HIV-1 infected children on ART is expected and compromises the 
benefits of HAART to reduce HIV-related morbidity and mortality
59
. In general, the children develops 
DRMs that lead to virologic failure within the first year on first line ART regimen
60
. International 
ART guidelines for infants recommend initiation of ART immediately due to the high risk of rapid 
disease progression among children
27
. In resource-limited settings infants and children are likely to 
have been previously exposed to ART during pMTCT programs; therefore, this population is likely to 
acquire resistance mutations. DRMs will persist as minority variants, thus predisposing these to 
virologic failure if these individuals require ART later-on in their lives. 
 
Studies have shown that at least 95% of adherence to HAART is required to prevent the development 
of DRMs which may result to therapy failure, thus compromising long-term benefits of ARV drugs in 
children 
57
. Common causes of poor adherence are usually complex and associated to social issues 
namely: poor treatment literacy, side-effects, depression and mental illness, poverty, work-related 
issues, substance use, social problems, denial and pill burden
17
. Children have unique challenges 
related to ART adherence such as complex dosing regimens, lack of availability of paediatric fixed-
dose combinations and poor drug palatability 
57
. In addition challenges such as poor socio-economic 
factors and the literacy levels of caregivers who are usually grandparents may lead to sub-optimal or 








Minimising drug resistance mutations fixed drug combinations and simplified ART strategies are 
important ways to maintain treatment options as children move through adolescence and possibly 
reach adulthood 
61
. Therefore, in order to provide effective ART for  HIV patients, it is essential to 
understand the mechanisms and the factors that contribute to the development of drug resistance 
62
. 
Among children the development of DRMs is worrying especially with the long term data on children  
DRMs not available
52
. Furthermore, the development of drug resistance in children is a great concern 
and should be minimised so that future ART options may be available through adolescence and  even 
to adulthood
63
. Currently, HIV drug resistance testing has  proved to be a powerful tool to monitor the 
development of DRMs 
62
.   
 
2.6 Detection methods for HIV-1 drug resistance mutations 
Since the ART scale-up, the rapid emergence of DRMs has become common
17
 . The developing 
countries including South Africa should focus on maintaining virologic suppression in patients on first 
line ART
17
 by providing simplified first-line regimen for children and adherence support
64
. In order to 
preserve and maximise the use of ART
17
. The primary goal of drug resistance testing should be to 
provide necessary information to assist in the selection of ARVs more likely to maintain viral 
suppression for a long period of time for a better patient’s management 
58
. Since South African drug 
resistance testing guidelines recommends that drug resistance genotyping for all patients (children and 




2.6.1 Sanger sequencing method   
Until a few years ago the standard method used for sequencing was the Sanger sequencing method 
first described in 1977
66
.This technique involves DNA sequence production carried out with capillary-
based semi-automated technologies based on dye-terminator Sanger biochemistry
67
. However, Sanger 
sequencing is only sensitive to >20%, where genomes are occurring in the majority will be 
sequenced
68
. Currently, the use of  genotypic resistance testing involves DNA sequencing  of the pol 
gene comprising the protease (PR) and reverse transcriptase (RT) genes either in its entirety or a 
portion thereof containing DRMs relevant to drugs currently in use
69
. The main barrier of genotypic 




Sanger sequencing testing involves DNA sequencing to detect DRMs within the genomic regions 
relevant to drugs currently in use such as the reverse transcriptase (RT) or protease (PR) genes
69
. 
Targeted region of the HIV genome is amplified using commercial assay kits e.g.TRUGENE and 
ViroSeq or in-house RT-PCR. Given that the main barrier of genotypic resistance testing to use in 
resource-limited settings is mainly related to cost
68
. Zhou et al 2011 investigated the cost and 
sensitivity between commercial assay kits and in-house RT-PCR and found that commercially 
available kits are not only insensitive to non-B subtypes but they are also more expensive when 
















2.6.2 Phenotypic method 
The phenotypic method involves  cell culture-based assay that measures the concentration of a drug 
pressure required to reduce replication of the virus (in vitro) 
69
. Susceptibility to protease (PR) and 
reverse transcriptase (RT) inhibitors is measured by using resistance test vectors (RTVs) that contain a 
luciferase indicator gene and PR and RT sequences derived from HIV-1 in patient plasma
71
. This 
method is not possible in the resource-limited setting for it requires a specialist laboratory and is very 
expensive to run. Disadvantages of phenotypic methods are a considerable delay of reporting time due 
to the wait for culture growth (up to 2 weeks) and its lack of  sensitivity to detect minority DRMs
71
. 
The phenotypic methods can be used when new anti-HIV compounds are being developed to 
determine their activity against highly drug-resistance patient isolates
72
. However, for clinical 
purposes this method is difficult to use due to the difficulty of correlating individual mutations with 




2.6.3 Allele-specific PCR (AS-PCR) 
AS-PCR is an allele identification real-time PCR method that is used to detect the genotype of samples 
by identifying a single mutation in a targeted region. It involves an allele-specific primer set and 
probes specific to the mutant and wild type variants
73
. AS-PCR is able to detect variants at a frequency 
as low as ≤1% within a population
74
. Two of the most commonly used probes types are the Taqman 
and MG probes. These probes have comparable sensitivities and linear ranges of detection. However, 





Although AS-PCR has the limitation of detecting one specific mutation at a time
77
 its sensitivity, 
accuracy, reproducibility and cost-effectiveness  make it an effective tool for resistance surveillance of 
minority DRM s in HIV-1 infected patients
77
. Especially when the key mutations are anticipated for 
instance Y188C or K103N  in nevirapine (NVP) exposed children during pMTCT  intervention
15
. 
Hunt al 2011, compared this method to population sequencing assay in their paediatric cohort (n=255) 
that was initiated on LPV/r-based ART regimen and were previously NVP-exposed. These children 
were all screened for the NNRTI key mutations: K103N and Y181C before switching them back to a 
cheap and tolerant NNRTI-based regimen. From both assays the combined results were as follows: 
zero - 6 months of age infants  harboured  61.9% NNRTIs mutations before starting ART, 6 – 12 
months of age children harboured 38.6% mutations, 12-18 months old of age children had 22 % 
mutations and 18 -24 months of age children 15.5% had persisting mutations occurring as  minority 
variants detected only by AS-PCR. The children with NNRTI mutations were likely to fail when 
switched back to NNRTI-based regimen
15
.   
 
In a resource-limited setting minimising the cost and the emergence of DRMs is important to ensure 
the effectiveness of a limited number of ART regimens. Therefore, AS-PCR analysis can be used as  
cost-effective analyses of choice for DRMs as oppose to a costly population sequencing analysis
15
. 
Given that South African guidelines recommend that all HIV-infected children should start ART 
immediately. However, that is also the period when DRMs are high and could compromise ART. 
Therefore, ART regimen should be chosen correctly, AS-PCR can be used to screen for DRMs and 
detect minority variants that can hinder future ART regimens and  monitor patients in an efficient way 











2.6.4 Next generation sequencing (NGS) 
The increase in national and international ART scale-up has necessitated the development of more 
sensitive, high throughput and cost-effective DRM testing methods. qPCR approach was the first to 
emerge with AS-PCR demonstrating excellent performance characteristics, detection limits and cost-
effectiveness 
15
. However, this method is limited to detecting just one DRM per reaction making a 
high-throughput approach unachievable.  Over the past few years NGS platforms have become widely 
available including Illumina and Ion Torrent and Roche systems
67
. NGS platforms are different from 
both Sanger sequencing and AS-PCR methods because they use massively parallel sequencing that is 
high throughput (up to 96 to 384 samples/run) and provides a snapshot of the entire virus population in 
a single run
67
.  Not only can specific genes but the entire genome be interrogated for resistance 












































3. Materials and Methods 
3.1 Ethical statement 
The study was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-
Natal (ref. BF052/10) and the Health Research Committee of the KwaZulu-Natal Department of 
Health (HRKM 176/10). 
 
3.2 The setting 
This study was conducted within the Hlabisa area, a sub-division of uMkhanyakude district situated in 
predominantly rural northern KwaZulu-Natal which is one of the epicentres for HIV-1 subtype C 
burden in the world (Fig. 5), with a prevalence of 5% in children aged 0-14 years. Details of the 
programme have been previously described
80
. Briefly, the programme employs a public health 
approach to ART delivery for the patients from this area facilitating a rapid scale-up of HIV treatment 
services at the 17 primary health care clinics and one district hospital
80
. The treatment and care is 
provided free of charge; however, the infrastructure is typical of many other rural health districts in 
South Africa having a limited-resource setting. The programme adheres to the South African 
eligibility criteria stating that all children less than 5 years irrespective of CD4 should start ART 
immediately, older children between 5 and 15 years of age should start based on their WHO clinical 
stage 3 or 4 or CD4 <350 cells/ul (Table 2)
6
. At the time of the study, children eligible for ART aged 
0–3 years (or weight under 10 kg) were initiated on a protease inhibitor  (PI) based regimen while 
children older than 3 years were initiated on a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-
based regimen
6
. All patients were seen weekly, fortnightly or monthly by a nurse and counsellor for 
the ART collections and the patients counselling session is conducted prior to receiving ART 
medication. Basic clinical and demographic data is collected on a standardised clinical form in parallel 
to the records in the Africa Centre’s ART evaluation and monitoring System (ARTemis) that is an 
operational database holding treatment and laboratory monitoring information
18, 81
. Some of the steps 
followed on the patient visit: 
 The counsellor informed the caregivers accompanying the child, as well as the child 
about the resistance study and gave them information sheet (Appendix 3). 
 The caregivers provided written informed consent (Appendices 4 and 5) and the 
children older than 12 years of age also provided their own written consent. 
 A  virologic failure clinical history sheet (appendix 6 ) including details of ART 
drugs, a record of each viral load and CD4 count and adherence (clinical and social) 
and history on Mycobacterium tuberculosis treatment and pMTCT was completed for 






Figure 5: The locations within Hlabisa demographic surveillance area, where patient recruitment and 
sample collection was conducted
82
 In panel A: green indicates KwaZulu Natal province, red indicates 
Hlabisa demographic surveillance area.  In panel B: red crosses indicates 17 clinics within the Hlabisa 
sub-district where sample collection was conducted and yellow triangle indicates Africa Centre’s 
location within an area 













3.3 Study design and sample size 
This was a retrospective study conducted on HIV-1 infected  infants and children ≤ 15 years of age 
with virologic failure (defined as two consecutive viral loads >1000 copies/ml) who had been 
receiving ART for at least a year at the time of HIV drug resistance genotyping. The study was 
conducted from August 2011 until the end of June 2014
81
. The children from 17 clinics within the 
uMkhanyakude sub-district, a total number of 119 patients were recruited and included into the Africa 
Centre paediatric resistance cohort. Of the 119 children, 38 children were included in this study. We 
selected (Fig. 6) all children that were initiated on PI first-line regimen (n=17) and never had 
experienced an NNRTI-based regimen, with an exception of those who had received NVP during 
pMTCT. Plus (n=21) initiated on NNRTI first-line based regimen were also selected for comparison. 
Children 16 years and older were excluded from the study and referred to the adult resistance cohort if 
experiencing virologic failure also managed by the Africa Centre. Details of patient’s recruitment have 
been reported previously
81
. For any child at virologic failure 5ml EDTA whole blood sample for HIV 
drug resistance genotyping collected during the clinical evaluation and sent to the Africa Centre 
laboratory in Durban, South Africa for testing. 
 
 
Figure 6: Flow chart showing the patients included and excluded from the analysis 







 Patients on PI Regimen 
(n=17) 
Patients included for 
analysis (n=13) 
Patients excluded (n=4) 
depleted sample (n=2) 
failed to amplify (n=2) 
 Patients on NNRTI  
Regimen (n=21), 




3.4 Africa Centre Laboratory 
All laboratory methods were conducted at the Africa Centre Laboratory (ACL), a Welcome Trust 
funded research institute situated approximately 220 kilometers south of Mtubatuba at the UKZ 
medical school, Durban. The laboratory conducts HIV serology, HIV viral loads (qPCR), in-house 
polymerase chain reaction (PCR), genotyping using Sanger sequencing and NGS using Illumina, 
Miseq.  
 
3.5 Laboratory methods 
3.5.1 Sample collection  
Approximately 5ml EDTA whole blood sample was collected during the clinical evaluation of the 
patient from one of the 17 sites and sent to Africa Centre laboratory for HIV drug resistance testing. 
The samples were collected as the part of paediatric ART failure cohort through Hlabisa HIV 
treatment and Care programme (PHC). EDTA blood samples were received at the laboratory on ice 
within 8 hours of collection. The basic clinical data was recorded in the laboratory information 
management system (LIMS). The plasma was harvested within 18 to 24 hours of sample collection 
and stored immediately at -80◦C until further use.  
 
3.5.2 HIV RNA extraction 
HIV RNA was extracted from the plasma using the manual QiAmp Viral RNA mini kit (Qiagen). This 
protocol is modified to extract RNA from 200µl plasma spun for an hour at maximum speed to 
concentrate the viral RNA for better amplification rates instead of 140µl, this protocol is previously 
described
18
. HIV RNA was eluted using 60µl of the elution buffer and then HIV RNA extract was 
stored immediately at -80◦C to prevent the RNA from degrading until further use.   
 
3.5.3 Resistance genotyping using Sanger capillary sequencing method 
3.5.3.1 In-house PCR 
An affordable and open access Southern African Treatment Resistance Network (SATuRN) drug 
resistance method previously described 
18
, was used. HIV RNA was reverse transcribed into cDNA 
using the Superscript III First-Strand Synthesis kit (Life Technologies, Carlsbad, CA) and RT21 gene 
specific primer (CTGTATTTCAGCTATCAAGTCCTTTGATGGG), this protocol is summarised in 
Table 4. Amplicons (Fig. 7) were generated from 3µl of the cDNA in a total reaction volume of 25µl 
followed by a nested PCR. The list of primers is listed in Table 5 and amplification protocol outlined 




















Table 4: Master Mix for cDNA synthesis using superscript III polymerase 
MM1 
Reagent Volume/Sample(µl) Final concentration 
Sterile Water 0.0 0 
RT21 (20mM) 0.5 0.2 m.M 
dNTP Mix (10 mM) 0.5 0.4 m.M 
Volume/Sample 1.0  
Add 6ul of RNA to the MM1 for each of the samples. 
Prepare MM2 as per table below, do not aliquot this mix. 
MM2 
Reagent Volume/Sample(µl) Final concentration 
10 x Buffer 1.0 1X 
MgCl (25mM) 2.0 4mM 
DTT (0.1M) 1.0 0.008M 
RNAse Out (40U/μl) 0.5 1.6U/μl 
SuperScript III 0.5  
Volume/Sample 5  
Cycling conditions for reverse transcription using superscript III polymerase 
Temperature (°C) Time (minutes) 
65 5 
4 2 
Pause to add  5µl MM2 for the synthesis of cDNA (total volume of 12µl) 
50 60 
85 5 















Figure 7: A diagram showing the primers and their positions covering protease and reverse 























Table 5:  Summary of primer sequences used for the first and second round nested in-house PCR for 
pol gene amplification 
Stage Primer 
name 














23     
Forward  





31      
Reverse  











Pro-1 TAGAGCCAACAGCCCCACCA 20 Forward 
2147-
2166 

































Table 6:  First round and second round Master Mix for nested in-house PCR 
First round  Master Mix 
Reagent Volume/Sample(µl) Final concentration 
Sterile Water 18.4 0 
10 x Buffer 2.5 4 
MgCl (50mM) 1.0 2 
dNTP (10mM) 0.5 0.2 
MAW26 (5 pmol/ul) 0.25 0.1 
RT21 (5 pmol/ul) 0.25 0.1 
Platinum Taq 0.1 0.02 
Volume/Sample 23  
Template (cDNA) 2.0  
Total Reaction Volume 25  
Second round  Master Mix 
Reagent Volume/Sample(µl) Final concentration 
Sterile Water 18.4 0 
10 x Buffer 2.5 4 
MgCl (50mM) 1.0 2 
dNTP (10mM) 0.5 0.2 
PRO1 (5 pmol/ul) 0.25 0.1 
RT20 (5 pmol/ul) 0.25 0.1 
Platinum Taq 0.1 0.02 
Volume/Sample 23  
Sample 2.0  
Total Reaction Volume 25  
The cycling conditions for the nested in-house PCR 
Temperature (°C) Time  Number of cycles 
94 2 minutes Hold 
95 30 seconds  
30 cycles 58 20 seconds 
72 2 minutes 
72 10 minutes Hold 
 
 
3.5.3.2 Agarose gel 
To assess the success of the PCR reaction, second round PCR products were stained with a fluorescent 
dye called novel juice (GeneDireX, Taipei Taiwan) and visualised using 1% agarose gel 
electrophoresis (45 min at 70V and 400 mA) under ultra-violet light. A 200-bp DNA ladder from 
(Fermentas, Maryland, USA) was used as a reference for the desired positive 1.3 kb PCR products. 
Successfully amplified PCR products were purified using the PureLink PCR purification kit (Life 





3.5.3.3 HIV genotyping using Big Dye terminator chemistry 
Sequencing reaction was done on purified PCR products using Big Dye ® terminator V3.1 (Applied 
bio-systems Inc., Foster City, CA) protocol outlined in Table 7 and a summary of gene specific 
primers listed in Table 8. Following the sequencing reaction, sequencing products were purified to 
remove any excess primers, unincorporated dye terminators, salts or enzymes. The plate clean-up was 
done using sodium acetate precipitation reaction method with ethanol washes. DNA pellet was 
reconstituted in 10µl of formamide and denatured at 95ºC for 2 minutes before running on a 3130xl 
Genetic Analyser (Applied Biosystems Inc, Foster City, CA).   
 
Table 7:  Master Mix for Big Dye terminator chemistry sequencing reaction  





Prepare the master mixes as follows: 
 
Reagent Volume/Sample(µl) 
Sterile Water 6.10 
Big Dye Ready Reaction mix 0.40 
Primer (3.20pmol/μl) 0.50 
5X sequencing buffer 2 
Volume per sample 9 
Template (DNA) 1 
Total Reaction Volume 10 
The cycling conditions for the big dye sequencing reaction 
Temperature (°C) Time  Number of cycles 
94 2 minutes Hold 
95 30 seconds  
35 cycles 58 20 seconds 
72 2 minutes 















Table 8: The summary of primers used in sequencing reaction of the pol gene 
Primer name and direction Sequence Size HXB2 (p) 
RTC1_Forward  ACCTACACCTGTCAACATAATTG 23 2486-2508 
    
RTC2_Reverse TGTCAATGGCCATTGTTTAACCTTTGG 27 2630-2604 








    
RTy _Reverse GTGTCTCATTGTTTATACTAGG 22 2967-2946 
    
MAW 46_Forward TCCCTCAGATCACTCTTTGGCAACGAC 27 2251-2277 
 
3.5.3.4 Sequence assembly and quality analysis 
Electropherograms generated from the Sanger sequencing were imported into Geneious V8.0.5 
software (www.geneious.com), the quality of the reads for each of the four primers was manually 
assessed and poor quality bases at the 5’ and 3’ ends were trimmed to improve the quality of each 
sequence. The sequences were manually edited and deemed high quality if the quality score was 
higher than 80% after trimming. A consensus sequence covering 300 amino acids of RT and 99 amino 
acids of the protease gene was generated following assembly of the four fragments. The first 240 
codons of the RT gene cover all currently recognised RT mutations associated with resistance to 
available RT inhibitors.   
 
Once trimmed and manually edited the sequences were aligned to a subtype C reference (Genebank, 
accession # JN665021.1) sequence to generate a contig. The contig sequence generated from an 
assembly was manually edited by reading through each sequence for possible base mixtures, deletions 
and insertions at different sites. Thereafter, the quality assessment and HIV subtyping of these 
sequences were performed using the HIV-1 Quality Analysis Tool and REGA HIV-1 Subtyping Tool 
v. 2.0, respectively. Firstly, the quality of the sequences was assessed using the HIV quality analysis 
tool hosted on BioAfrica.net. The sequences were analysed using the Stanford HIVDB programme 
accessed on the mirror of the Stanford database also hosted on BioAfrica.net. Prior to the detection of 
DRM using bioinformatics software applications, we submitted each consensus to the Calibrated 
Population Resistance Tool (CPR) (http://hivdb.stanford.edu) for a final quality check.   
 
To test for contamination the sequences were blasted against the public dataset using NCBI blast 
(http://www.ncbi.nlm.nih.gov/ blast) as well as a local database using a Blast Server application. 
Sequences were deemed not a contaminant if the identity to previously genotyped samples was lower 
than 98%. Post quality assessment the sequences were loaded onto the SATuRN database. This 
database uses the online drug resistance algorithms (ANRS 2009.07, HIVDB6.0.5 and REGAv8.0.2) 








3.6 Next generation sequencing 
3.6.1 Amplicon generation 
Fig. 8 depicts HIV-1 whole genome sequencing sample preparation from extraction to sequencing for 
Miseq, Illumina. Briefly, HIV RNA was used to synthesise cDNA using the SuperScript III one-step 
RT-PCR with platinum
 
Taq high fidelity previously described at a temperature of 50°C for 30 
minutes
83
. Amplification was performed in the same tube (one-step) using SuperScript III-Platinum 
Taq High fidelity enzyme mix and 5µl of RNA to synthesise four overlapping amplicons that span the 
near full 9.7kb HIV genome
83
 (Table 9) and gene specific primers listed in Table 12. The amplicons 
generated Pan 1 of 1.9kb, Pan 2 of 3.6kb, Pan 3 of 3.0kb and Pan 4 of 3.5kb respectively including all 
9 open reading frames as well as the U5 and partial R region of 5’-LTR and the partial U3 of the 3’-
LTR shown in (fig. 9)
83
  .  
 
In the event of 1 to 2 fragments failing to amplify, we used a separate RT and PCR reaction using the 
reverse gene specific primer and SuperScript III First-Strand Synthesis Kit (Invitrogen) for reverse 
transcriptase and then Platinum Taq High Fidelity DNA Polymerase (Invitrogen) for amplicons 
generation. For cDNA synthesis 5µl of RNA was used in a 12.5µl reaction volume and final primer 
concentration of 1.6µM (Table 10). Amplicons were generated using Platinum Taq High Fidelity 
DNA Polymerase (Invitrogen) (Table 11) and gene specific primers listed in Table 12. All positive 
amplicons were visualised on a 1% agarose gel and then purified using the QiaQuick PCR Purification 
































Table 9:  Master Mix for SuperScript III one-step RT-PCR using platinum
 
Taq high fidelity enzyme  
Reagent  Vol/sample (μl) Vol in MM (μl) 
Sterile water 4.5 72 
2x Reaction Buffer 12.5 200 
Pan1-4 primer mix (10pmol/µl each) 2.0 32 
SSIII/Platinum Taq polymerase (5U/µl) 1.0 16 
Volume/sample 20.0 
 Template (HIV RNA) 5   
Total reaction volume 25  
The cycling conditions for superscript III one-step RT-PCR 
Temperature (°C) Time Number of cycles 
50 30minutes Hold 




68 4.5 minutes 
68 10minutes Hold 
4 ∞ Hold 




























Table 10:  Master Mix for cDNA synthesis using superscript III polymerase 
MM1 
Reagent Volume per sample(µl) Final concentration 
Sterile Water 0.0 0 
Primer-R(20µM) 1.0 0.5 m.M 
dNTP Mix (10 mM) 1.0 2.5 m.M 
Volume/Sample 2.0  
Template(HIV RNA) 5.0  
Total Reaction volume 7.0  
Prepare MM2 as per table below, do not aliquot this mix. 
MM2 
Reagent Volume/Sample(µl) Final concentration 
5xBuffer 2.5 1X 
MgCl  1.0  
DTT (0.1M) 0.75 0.01M 
RNAse Out (40U/μl) 0.75 2U/µl 
SuperScriptIII (200U/μl) 0.75 10U/µl 
Volume/Sample 5.75  
The cycling conditions for reverse transcription using superscript III polymerase 
Temperature (°C) Time (minutes) Hold 
65 5 Hold 
4 2 Hold 
Pause to add  5.75µl MM2 for the synthesis of cDNA (total volume of 12µl) 
50 60 Hold 
55 60 Hold 
Pause to add 1ul of RNaseH Hold 
70 15 Hold 


















Table 11:  Master Mix for the RT-PCR using platinum
 
Taq high fidelity polymerase 
 Reagent Volume per sample (µl) Final concentration 
Sterile water 16.20 0 
10x buffer 2.50 1X 
MgSO4 (50mM) 1.00 1X 
dNTP (10mM) 0.60 2.5mM 
Primer-F (20uM) 1.00 0.2mM 
Primer-R (20uM) 1.00 0.2µM 
Platinum HF(5U/µl) 0.20 0.025U/µl 
Volume/sample 22.50 
 Template(cDNA) 2.50  
Total reaction volume 25.00  
The cycling conditions for the RT-PCR using platinum
 
Taq high fidelity 
Temperature Time  Number of cycles 





68 10min hold 
4 ∞ hold 
 
 
Table 12: Summary of primers covering protease, reverse transcriptase and integrase regions used for 
amplification   
Set and primer Sequence (5'-3') Position(nt) Product size (bp) 
Pan-HIV-1_1F AGC CYG GGA GCT CTG TG 26-42 1928 
Pan-HIV-1_1R CCT CCA ATT CCY ATC ATT TT 1953-1931  
    
Pan-HIV-1_2F GGG AAG TGA YAT AGC WGG AAC 1031-1051 3574 
Pan-HIV-1_2R CTG CCA TCT GTT TTC CAT ARTC 4604-4583  
    
Pan-HIV-1_3F TTA AAA GAA AGG GGG GGA TTG GG 4329-4351 3066 
Pan-HIV-1_3R TGG CYT GTA CCG TCA GCG 7394-7377  
    
Pan-HIV-1_4F CCT ARG GCA GGA AGA AGC G 5513-5531 3551 

























Figure 9: An illustration showing the location of Pan 1-4 primers and amplicon size generated by each 
 
3.6.2 Genotyping using Miseq, Illumina 
The amplicons were quantified using the Qubit sdDNA HS Assay Kit (Thermo/Life Technologies, 
Oregon; USA). Each amplicon was diluted to a concentration of 0.3ng/µl before pooling in a 1:3:3:3 
ratio of Pan1 to Pan 4. Pooled amplicons were prepared for sequencing using the Nextera XT DNA 
sample preparation kit (Illumina) and the Nextera XT DNA sample preparation index kit (Illumina), 
following the manufacturers protocol. Normalisation of the libraries was bead-based, also as per the 
manufacturer's protocol and using the Nextera XT DNA sample preparation kit (Illumina). Libraries 
were pooled and sequenced on the MiSeq, Illumina using 300bp paired-end technology and the MiSeq 
Reagent Kit V3 (Illumina).  The run comprised pools of 96 samples that included 3 controls (one 
negative sample, one inter-run and one intra-run control).   
 
3.6.3 Assembly and consensus generation 
The generated reads were assembled using Geneious V8.0.5 software package to map and align all 
reads. The quality of the reads was manually assessed and the ends trimmed to improve the quality, 
before mapping and aligning to a subtype C reference sequence (Genebank, accession # AF411967) 
from South Africa. Reads <100bp were excluded and poor quality reads were trimmed up to 50bp 
from 5’ and 3’ ends. We imposed these inclusion and exclusion criteria in order to decrease the 
probability of ambiguous read mapping which occurs when shorter reads of lower accuracy are 
included in assemblies. 
 
3.6.4. Phylogeny 
The pol gene was extracted from 34 consensus sequences generated using NGS and aligned with 
consensus sequences generated using Sanger sequencing together with reference sequences 
representative of all major subtypes currently circulating.  We included a greater number of subtype C 
sequences from Southern Africa, Brazil and India in order to verify the subtype of our sequences given 
that South Africa has a predominantly subtype C epidemic. Alignments were generated in ClustalW 
84
 
and then manually edited in Geneious V 8.1 (www.geneious.com). Trees were generated using 
RAxML
85
 and a general time reversible  model with an estimated gamma heterogeneity alpha 
parameter and 1000 bootstrap replicates to estimate the reliability of internal nodes.  We used FigTree 




3.6.5. Detection for drug resistance mutations 
A set of 34 sequence reads >301 base pairs were obtained and uploaded onto the Geneious V8.0.5 
software system. The sequences were trimmed between 100bp and 301bp, mapped and assembled 
against full-length HXB2 subtype C (Genebank, accession # AF411967) reference sequence. The 
reference sequence used was annotated with HIV DRMs of interest at the pol gene as outlined in the 
Stanford HIV drug resistance 2013 database (http://hivdb.stanford.edu). Too short sequences and 
sequences that were of the poor quality according to the statistical scoring requirements were excluded 
from the analysis.  
 
Contig from each sample was mapped against a reference sequence to find minority DRMs with a 5% 
variant call cut-off to exclude the impact of polymerase introduced errors. We identified 
polymorphisms with a 5% variant call cut-off to exclude the impact of polymerase introduced errors. 
The table list of motifs and polymorphism was extracted and exported as a working excel table. To 
analyse minor DRMs: read depth and frequencies of mutations associated with drug resistance, as 
outlined in the Stanford HIV drug resistance database were analysed. The use of an annotated 
reference sequence allowed us to confirm the presence of minority resistance calls at DRMs located at 
the contig. DRMs present at a proportion ≥20% were regarded to be wild type and those present at a 
proportion <20% were considered to be minority DRMs 
 
3.7 Statistical analysis 
In order to investigate the DRMs in this cohort, the drug resistance mutations, clinical measurements 
and demographic data were exported for all patients genotyped from RegaDB for further statistical 
analysis using STATA version 10 (StataCorp LP, Texas, USA). Descriptive statistics were used to 
summarize the demographic and clinical characteristics in this cohort. For analysis of drug resistance 
mutations, frequency distributions of the major DRMs were derived and 5% level of significance to 
investigate minority DRMs was selected. Medians and the interquartile range (IQR) were calculated 
for continuous data. 
  
3.8 Interpretation of resistance results and report generation 
Sanger genotyping results for this cohort including drug resistance profile for each sequence together 
with the clinical data and treatment history (Appendix 6) of the patient’s was used to generate a drug 
resistance report (Appendix 8). The report contained DRMs identified from the patient virus and drug 
resistance interpretation based on the HIVDB version 6.0 algorithms was generated and sent to an 
Infectious Disease Specialist who evaluated the report together with the patient’s clinical data and 
provided treatment recommendations based on the current South African guidelines (Table 1). The 
report also contained genotypic susceptibility scores (GSS) where a GSS of 1.0 indicates drugs that are 
still active against the virus, 0.5 indicates drugs that have intermediate resistance and 0.0 is indicative 
of high-level resistance (Figure 10). However, NGS analysis was done retrospectively only for 


















4.1 Study Population 
The demographic and clinical details of this cohort are summarised in Table 13. Briefly, a total 
number of 34 patients were included in the analysis with 20 (58.8%) males with a median age of 1.4 
(IQR 0.6-4 years). Twenty-one children (61.7%) were enrolled on an NNRTI-based regimen while the 
remaining 13 were initiated on a PI regimen.  Children on a PI-regimen were significantly (p=0.0029) 
younger in age at initiation with a median age of 0.7 (IQR 0.6-1.4 years) compared with those on an 
NNRTI regimen with a median age of 7.1(IQR 3.4-10 years). Patients were genotyped at virologic 
failure following two successive viral load measurements >1000cp/ml.The median age at genotype 
was 6.6 years (IQR 4.5-11.7), (Table 13). The median time between the date of genotype and the last 
viral load was 3.4 months (IQR 1.5-8.3 months), (Table 13).   
 
For CD4 measurements this time period was 6.2 months (IQR 3-9 months). Children from NNRTI-
based regimen group had been on ART for longer period than those on PI-based regimen group.  
Interestingly, among children on PI-based regimen only 15.3% had ever achieved virologic 
suppression (a confirmed HIV RNA cp/ml level below the limit of detection) compared to 53.2% of 
those on NNRTI-base regimen. Of the 34 patients in our cohort, twenty patients had at least one drug 
substitution in their regimen with 13 patients having drug substitution prior to genotyping and seven 
patients who had a drug substitution after genotyping. Due to drug toxicity in 2013, the South African 
Department of Health recommended replacing d4T with ABC if the VL is undetectable
6
. In this cohort 
only six children were subject to this recommendation and had a drug substitution of ABC replacing 
d4T in their regimen and among other fourteen drugs substitution was due to virologic failure. The 
remaining 14 patients in the cohort were maintained on the same regimen that they had been on prior 
to genotyping. More patients on PI-regimens (n=5) were exposed to single-dose nevirapine (sdNVP) at 


























Table 13:  Demographic and clinical data of the 34 children on non-nucleoside reverse transcriptase 
and protease inhibitors based regimen groups at ART initiation and at the time of genotype 
Characteristic All patients  
(n = 34) 
PI-based 
(n = 13) 
NNRTI-based 
(n = 21) 
Gender, male, n (%) 20 (58.8) 7 (53.8) 13 (61.9) 
Age at ART initiation, years, median (IQR) 











10-15 years  
17 (50.0) 
  3 (8.8) 
  9 (26.5) 









Age at genotype,  
years, median (IQR) 
 



























8  (38.1) 
12 (57.1) 
CD4 at ART initiation, cells/µl 
median (IQR) 
 
Number of patients by CD4 categories: (%) 
 







<50  cells/µl 
50 – 200 cells/µl 
201 – 500 cells/µl 
501 – 1 000 cells/µl 
















CD4 prior to genotyping, cells/µl 
median (IQR) 
 
Number of patients by CD4 count categories: 
(%) 
<50 cells/µl 
50 - 100 cells/µl 
101 - 200 cells/µl 
































Viral load at ART initiation, log10 copies/ml  
median (IQR) 
 
Number of patients by viral load categories: (%) 
≤ 2 log10 copies/ml  
2 - 3 log10 copies/ml 
3 - 4 log10 copies/ml 
4 - 5 log10 copies/ml 
> 5 log10  copies/ml 
 
4.2 (3.51 – 
5.23) 
 
3  (8.8) 
4  (11.8) 
6  (17.7) 





















Viral load prior to genotype, log10 copies/ml  
median (IQR) 
 
Number of patients by viral load categories: (%)
 
<2 log10 copies/ml 
2-3 log10 copies/ml 
3-4 log10 copies/ml 
4-5 log10 copies/ml 
> 5 log10  copies/ml 
 



























Time between last CD4 and genotype 








Time between last VL and genotype  







Ever achieved virological suppression, 















Duration of antiretroviral therapy since ART 
initiation  











Duration of antiretroviral failure, 




14.2 (9.9-31) * 
 
23.2 (14.9-32.8) * 























Number of patients by ART regimen at the time 






































Number of patients with history of drug 
substitution 























9  (42.8) 
7  (33.3) 
5  (23.8) 
Number of patients with Single-dose nevirapine 
























IQR, interquartile range, ART, antiretroviral therapy, PI, Protease inhibitor, NNRTI, non-nucleoside 
reverse-transcriptase inhibitor, 3TC, lamivudine, d4T, stavudine, ABC, abacavir, AZT, zidovudine, 
TDF, tenofovir, DDI, Didanosine, EFV, efavirenz, NVP, nevirapine, LPVr, lopinavir/ rotinavir, 1 = 
Refers to the last viral load measurement documented prior to date of genotype, 2 = Duration of 
antiretroviral failure was calculated from the date of the first viral load >1000 copies/ml, If there was 
no viral load <1000 copies/ml then time was calculated from date of ART initiation, 3= Substitution 



























4.2 Clinical characteristics of children  
The median age at the time of ART initiation was 3 years (IQR 1-8.3). Children on PI-based regimen 
group were initiated at 0.7 years (IQR 0.6-1.3), significantly (p=0.0029) younger in age compared 
with those on an NNRTI regimen. We noted that four children younger than 3 years of age were 
incorrectly initiated on an NNRTI-based regimen (3TC+D4T+ EFV)
6
 such that only one patient in this 
age group was correctly initiated on PI-based regimen. Seven of the 34 children were exposed to 
sdNVP for pMTCT, five from PI-based regimen group and two from NNRTI-based regimen group.  
 
The median VL at ART initiation was 4.2 log10 copies/ml (IQR 3.5-5.2) with comparable viral loads 
between the NNRTI group (median = 4.2 log10 copies/ml, IQR 3.6-5.4) and PI groups (4.4 log10 
copies/ml, IQR 3.5-4.9). However, the median CD4 at the time of ART initiation was significantly 
higher among patients initiated on a PI-based regimen (p>0.05). At the time of genotype children from 
NNRTI-based regimen group were significantly older than those on PI-based regimen (p=0.0500). The 
median duration of 23.2 months (IQR 14.9-32.8) on ART failure was  longer for children on NNRTI-
based regimen group than those on the PI-based regimen group with 14.2 months (IQR 9.9-31). 
Children on the NNRTI group remained on a failing regimen for significantly (p<0.01) longer than 
those in the PI group (Table 13). At genotype, we noted no significant differences in viral loads 
(p>0.05) when comparing both groups (Table 13). Similarly, CD4 counts prior to genotyping were not 

































4.3 Drug resistance mutations detected by Sanger sequencing 
We generated population amplicons of a 1.3kb region of the pol gene and sequenced this amplicon 
using the Sanger sequencing platform. Of the 34 patients in the cohort we failed to generate a 
sequence from one patient using the Sanger sequencing platform. For the remaining 33 patients 
sequences of >75% quality were used in the assembly and generation of a consensus sequence.   
 
Among these 33 sequences, we detected a mixture of major (79.5%) and accessory (23.8%) mutations 
in the pol gene that are associated with resistance to ARVs currently in use (Table 14,16, Fig. 10). 
Twenty-four (72.7%) children harboured at least one DRM, while 9 (27.2%) were completely 
susceptible to their regimens. NRTI-associated mutations were the most commonly occurring and 
were detected in 23 (69.6%) children with M184 being the most frequent NRTI mutation (n=22 of 33, 
66.6%). We detected at least one TAM in 7 (21.2%) children comprising four children with one TAM, 
two in six and multiple of ≥3 TAMs in one child. D67N TAM pathway II mutation predominated 
among these children. 
 
We noted that children from NNRTI-based regimen group, the M184 was the most commonly 
occurring mutation detected in 15(71.4%) of children on an NNRTI –based regimen (Table14, Fig.10). 
In comparison, the most common NNRTI-associated DRM was K103 which was present in 8 (38 %) 
children. TAMs were detected in 6 (28.5%) children. Six children had a complex mixture of cross-
resistance and TAMs suggesting an extended period of time on a failing therapy.  
 
Among children on PI-based regimens, we noted that 3(25%) had PI-associated drug resistance 
mutations. Included among the PI-associated mutations detected were the major V82A and I54V 
mutations, as well as the L10I/F and L24I accessory mutations (Table 14, Fig.10). NRTI-associated 
drug resistance mutations were the most prevalent mutations within this group with M184V the most 
frequently occurring NRTI mutation (n=7, 58.3%). One patient had a single TAM, the M41L 
mutation. No NNRTI-associated mutations were detected in this group where approximately 42% 
























Figure 10: A summary of all HIV-1 drug resistance mutations identified in the pol genome including thymidine analogue mutations (TAMs) from 33 




























Table 14: Frequency of major and minor drug resistance mutations associated with protease inhibitors, 
nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase regimens in 33 
children genotyped using Sanger sequencing 
DRMᶤ Overall patients 
(n=33)  
Number (%) 
PI-based regimen (n=12) NNRTI-based regimen 
(n=21) 
PI mutations  
Any mutation 3(9.0) 3(25.0)  
L10FI 2(6.0) 2(16.6)  
L24I 1(3.0) 1(8.3)  
I54V 1(3.0) 1(8.3)  




Any mutation 23(69.6) 7(58.3) 16(76.1) 
M41L 3(9.0) 1(8.3) 2(9.5) 
A62V 1(3.0)  1(4.7) 
K65R 2(6.0)  2(9.5) 
D67N 4(12.1)  4(19) 
T69D 2(6.0) 1(8.3) 1(4.7) 
L74V 2(6.0) 1(8.3) 1(4.7) 
V75IM 4(12.1)  4(19.0) 
Y115F 1(3.0) 1(8.3)  
M184V 22(66.7) 7(58.3) 15(71.4) 
L210W 1(3.0)  1(4.7) 
T215F 2(6.0)  2(9.5) 
K219QRW 3(9.0)  2(9.5) 
TAMs 
Any TAMs 7(21.2) 1(8.3) 6(28.5) 
1 TAM 4(12.1) 1(8.3) 3(14.2) 
2 TAMs  2(6.0)  2(9.5) 




Any mutation 17(51.5) 17(80.9) 17(80.9) 
K101EIHN 4(12.1) 4(19.0) 4(19.0) 
K103NRST 8(24.2) 8(38.0) 8(38.0) 
V106M 1(3.0) 1(4.7) 1(4.7) 
V108I 1(3.0) 1(4.7) 1(4.7) 
V118I 1(3.0) 1(4.7) 1(4.7) 
E138A 2(6.0) 2(9.5) 2(9.5) 




Table 14: Frequency of major and minor drug resistance mutations associated with protease inhibitors, 
nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase regimens in 33 
children genotyped using Sanger sequencing (continued) 
Y181C 1(3.0)  1(4.7) 
Y188CL 2(6)  2(9.5) 
G190AEQ 5(15.1)  5(23.8) 
P225H 3(9.0)  3(14.2) 
Susceptible 9(27.2) 5(41.6) 4(19.0) 
 Bold font indicates accessory mutations, regular font indicates major mutations 
 All identified drug resistance mutations were defined using IAS-USA mutation list _2013 




































4.4 NGS  
4.4.1 Data quality 
In order to examine the patterns and prevalence of DRMs at minority frequencies, we performed ultra-
deep next generation sequencing using the Illumina MiSeq platform.  Each sample generated a total 
number of sequence reads that averaged >300 000 but following quality control of the data (trim 5’ 
and 3’ end, discard <Q25 and reads <100bp) approximately half that number were used in the final 
assembly (mean = 179 731 reads).  We achieved a mean depth of coverage of the assembly of >4 
600x; however, this varied over the entire genome. We noted that the average coverage over positions 
relevant to drug resistance codons varied considerably with the highest depth of coverage noted at the 
M184V position while the V32E/L, K103T, Q151M, E138A Y181C, Y188C/S, T215I and M230L 
codons did not have notable depth of coverage (Table 15). We used 3 different thresholds to 
investigate the impact of minority DRMs namely: 1%, 5% and 10% and will present the findings of 
this comparison subsequently. 
 
4.4.2 Drug resistance mutations detected by NGS 
Among 34 near complete HIV genomes generated (34 included children) using NGS, 29 (85%) 
harboured at least one DRM while five remained susceptible. At least one accessory DRMs was 
detected in 25 (73.5%) children. We noted that seven children harboured a mixture of NRTI, NNRTI 
and TAMs DRMs. While NRTI mutations were the most commonly occurring DRMs detected in 24 
(76.1%) children with M184 being the most prevalent (n= 22, 64.7%) of these.  NNRTI-associated 
mutations were less frequent occurring in 19 of 34 (55.8%) children. At least one TAM was detected 
in 9 (26.4%) patients, among those nine patients and five had at least three or more TAMs within the 
total viral population and four had at least one TAM each detected within their total viral population. 
We noted a child with no prior exposure to integrase inhibitors (IN) having major N155R intergrase-
associated mutation detected. Eleven children (32.3%) were found to be harbouring at least one 
minority drug-resistance mutation that was missed by Sanger sequencing (Table 15, 16, Fig. 11).  
 
Among patients on an NNRTI-based regimen group, we noted that NRTI mutations were the most 
frequent detected in 24(70.5%). M184 mutation was the most common NRTI mutation detected in 16 
(76.1%) children. NNRTI-associated mutations were detected in 15(71.4%) with K103 being the most 
common mutation detected in 9 (42.8 %) children. Six children (28.5%) had a mixture of NRTI, 
NNRTI and TAMs mutations. While at least one TAM was detected in 8 (38 %) children with D67N 
being the most common detected in six children. Of the 34 children, eight children (38%) were found 
to be harbouring minority drug-resistance mutations that were totally missed by Sanger sequencing 
(Table 15, 16).   
 
Even within the group of patients PI-based regimen group NRTI-associated mutations were the most 
frequently occurring mutations (Table 15), despite that these children were on PI-based regimen 
detected from 61.5% children. However, that was expected given that NRTIs forms a backbone for 
ARVs. Only 4 (30.7%) children had PI-associated mutations. One child had TAMs occurring as 
multiple TAMs, while four (30.7%) children were found to be susceptible. We noted a child who had 
never been on NNRTI-based regimen nor had experienced sdNVP during pMTCT to be harbouring 





Figure 11: A summary of all HIV-1 drug resistance mutation identified from the whole HIV genome including thymidine analogue mutations (TAMs) 












































































































































































































































Table 15: Frequencies of major and accessory drug resistance mutations associated with protease 
inhibitors, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase 







PI mutations n (%) n (%) n (%) 
Any mutation 6 (17.6) 4(30.7) 2 (9.5) 
L24I 1 (2.9) 1(7.6)  
D30NH 2 (5.8) 1(7.6) 1 (4.7) 
V32EL 1 (2.9) 1(7.6)  
L33V 1 (2.9) 1(7.6)  
M46IL 2 (5.8) 1(7.6) 1(4.7) 
I54V 1 (2.9) 1(7.6)  
L76AI 2 (5.8) 2(15.3)  
V82AI 3 (8.8) 3(23)  
NRTI mutations 
Any mutation 24(70.5) 8(61.5) 16(76.1) 
M41L 4(11.7)  4(19) 
A62V 1(2.9)  1(4.7) 
K65R 4(11.7) 1(7.6) 3(14.2) 
D67N 7(20.5)  7(33.3) 
T69DN 2(5.8) 1(7.6) 1(4.7) 
K70R 3(8.8)  3(14.2) 
L74V 3(8.8) 1(7.6) 2(9.5) 
V75IM 2(5.8)  2(9.5) 
Y115F 2(5.8) 1(7.6) 2(9.5) 
M184IV 22(64.7) 7(53.8) 16(76.1) 
L210W 2(5.8)  2(9.5) 
T215I 1(2.9)  1(4.7) 
K219EQ 4(11.7)  4(19) 
TAMs 
Any TAM 9(26.4) 1(7.6) 8(38) 
1 TAM 3(8.8)  3(14.2) 
2 TAMs  1(2.9)  1(4.7) 











Table 15: Frequencies of major and accessory drug resistance mutations associated with protease 
inhibitors, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase 
inhibitors in 34 genotyped children using next generation sequencing (continued) 
NNRTI mutations  
Any mutation 19(55.8) 4(30.7) 15(71.4) 
L100I 1(2.9)  1(4.7) 
K101EHN 2(5.8)  2(9.5) 
KI03NRST 9(26.4)  9(42.8) 
V106M 5(14.7) 1(7.6) 4(19) 
V179ADI 4(11.7) 3(23) 1(4.7) 
Y181C 1(2.9)   
Y188CLS 3(8.8) 1(7.6) 2(9.5) 
G190AEQ 2(5.8)  2(9.5) 
P225H 5(14.7)  5(23.8) 
M230L 1(2.9)  1(4.7) 




N155R 1(2.9)  1(4.7) 
Susceptible 5(14.7) 4(30) 1(4.7) 
 Bold font indicates accessory mutations 
 Regular font indicate major mutations 
 All identified drug resistance mutations were defined using IAS-USA mutation list _2013 

























4.5 Comparison between Sanger sequencing and NGS 
4.5.1Phylogeny 
All sequences were subtype C and clustered within the subtype C clade with high bootstrap support for 
each. Sequences for each patient derived from Sanger sequencing and those generated by NGS 
clustered together indicating that there was no cross-contamination between patient samples.  
 
4.5.2 Detection of minority drug resistance mutations 
A total of 108 DRMs were detected by NGS platform, 32 from PI based regimen group and 76 from 
NNRTI-based regimen group. While 88 DRMs were detected using Sanger sequencing; NGS detected 
an additional 24 DRMs, 22% more DRMs from what was detected using Sanger sequencing. Of those 
additional mutations 15 were minority DRMs present in 11 (32.3%) children (Table 17, Fig. 12). The 
minority DRMs percentage frequency ranged between 10.2% and 20.9% (Table 17). Minority DRMs 
detected includes: PI-associated mutations L76A (n=1), V82I (n=1), M46L (n=1) and D30H (n=1). 
NNRTI-associated minority mutations: Y188C (n=1), P225H (n=1), V179A (n=1). NRTI-associated 
minority variants detected were M41L (n=2), K65R (n=1), T69D (n=1), K70R (n=1), Y115F (n=1), 
M184I (n=1) and L210W (n=1) (Table 17, Fig. 12).We noted that among four children (three from PI 
and one from NNRTI-based regimen groups) when NGS was used, DRMs not associated with the 
ART regimen in use were detected. Of the three children from the PI-based regimen; two had a history 
of sdNVP. The other two children (including one from NNRTI-based regimen groups) the reason for 
these DRMs was unknown. We hypothesise that these DRMs could have been transmitted vertically or 


























Figure 12: A summary of the prevalence of HIV-1 drug-resistance mutations detected by Sanger and next generation sequencing. DRMs detected by 
Sanger sequencing are indicated in blue, DRMs detected by NGS are indicated in red and minority drug resistance mutations indicated in green which 



















Drug resistant mutations 




Table 16: Average sequencing read coverage and frequencies for all HIV-1 drug resistance mutations identified by Sanger sequencing and NGS 
Gene DRM Sanger 
sequencing 
NGS at 10% mutation frequency NGS at 1- 5% mutation frequency 















PR L24I 1 1 958 99 1 1045 96.3 
 D30N     1 28 10.7 
 D30H  2 8294 59.75 2 516 20.5 
 V32E  1 12 16.7 1 26 23.1 
 V32L  1 12 16.7 1 26 23.1 
 L33V  1 11 18.2 1 26 15.4 
 M46I  1 1125 98.6 1 1168 98.2 
 M46L  1 785 13.9 1 791 13.8 
 I54V 1 1 1088 98.7 1 1145 97.3 
 L76A  1 3327 98.9 1 4333 21.9 











Table 16: Average sequencing read coverage and frequencies for all HIV-1 drug resistance mutations identified by Sanger sequencing and NGS 
(Continued) 















 V82I     1 3546 21.3 
RT/NRTI M41L 3 3 9374 51.4 4 2082.2 40.8 
 A62V 1    1 6202 84.2 
 K65R 2 3 8567 86 4 3794.5 68 
 D67N 4 6 11849 87.8 7 2977 69.6 
 T69D 2    1 2123 89.1 
 T69N  1 4889 47.1 2 5550.5 32.1 
 K70R  3 1314 70 3 3297 61.3 
 L74V 2 3 14648 57.2 3 5179.6 56.3 
 V75M 2       
 V75I 2 1 2568 99.3 2 2312 98.3 
         
 Y115F 1 1 4377 98.9 2 4601 54 
 M184I     1 2139 12.8 
 M184V 22 17 56348 89 21 4312 82 
 L210W 1    2 6927.5 56 
 T215I 3 1 8 75 1 8 65.5 
 K219E 1 3 9382 99.8 3 3563.6 71.7 
 K219Q  1 3 100 1 1021 47.4 





Table 16: Average sequencing read coverage and frequencies for all HIV-1 drug resistance mutations identified by Sanger sequencing and NGS 
(Continued) 

















L100I     1 6033 96.9 
 K101E 1 1 1035 99.5 1 1096 97.9 
 K101Q     1 486 80.9 
 K103N 4 7 20849 91.6 7 3817.8 88.4 
 K103R 2 2 8737 90.6 2 3448 88.3 
 K103T  1 17 55.9 1 17 52.9 
 V106M  4 2904 97 5 3848.6 96.4 
 V179A     1 4527 19.8 
 V179D 1    2 1211.5 96.3 
 V179I  1 4475 68.5 1 4624 68.3 
 Y181C  1 6 33.3 1 819 18.3 
 Y188C 1 2 80 100 2 4779 38.9 
 Y188S  1 6 100 1 685 31.5 
 G190A 3 2 8126 86 2 4045.5 88.6 
 G190E  1 8695 99.3 1 8949 98.7 
 P225H 3 4 16439 98.6 5 4890.4 71.5 
 M230L  1 3 100 1 719 51.3 
 K238R     1 586 36.2 
 
 All identified drug resistance mutations were defined using IAS-USA mutation list _2013 (appendices 1 and 2) 
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L76A (20.9)*, V82A (76.9%), V82I 







M41L (10.4%)*, D67N (35.6%), 
V106M (98.7%), M184V (97.8%), 









#28 susceptible D67N (98.2%), K70R (98.2%), V106M 
(96%), M184V (42.2%), Y188C 







M41L (15.9%)*, D67N (21.3%)*, K70R 










K65R (98.2%), L100I (96.9%), K103N 





#56 M184V T69D (16.7%)*, L74V (30.7%), Y115F 















































ᵅ DRMs with asterisk were found to be occurring as minority variants in these children and only 
detected by NGS 
ᵇ 3TC (lamivudine), AZT (zidovudine), ABC (abacavir), DDI (didanosine), TDF (tenofovir), LPV/r 
(lopinavir boosted with rotinavir) 
ᶜ switched from NNRTI-based regimen to PI-based regimen 
 
4.5.3 Genotypic susceptibility score (GSS) correlations between drug resistance 
mutations detected and drug regimens   
We interpreted genotypic results using Rega V 9.1.0 genotypic susceptibility score (GSS) as a 
predictor of virologic failure (Fig. 13). Rega V 9.1.0 system reports three levels of resistance: 
susceptible (≤1), intermediate (≤0.5) and resistant (0). We noted that some of these patients had 
developed resistance to some ARV in use (NRTIs and NNRTIs) with an exception of PI drugs.  A 
total number of (24, 70.5%) children had developed resistance mutations to NRTIs, predominant 3TC. 
GSS scoring system showed that M184 mutation resulted in a high resistance (~65%) to 3TC, 
intermediate resistance (20%) to ABC and DDI, and low resistance (10%) to AZT and d4T. These 
finding were consisted with a high prevalence of M184 mutation in out cohort; therefore, high 
resistance to 3TC. However, high resistance to NRTI is of the great concern, given that NRTIs make 
up the backbone of ARVs in South Africa and other limited-resources countries. However, the 
majority of children were still susceptible to other NRTIs including ABC, AZT, d4T, DDI and TDF 
allowing these children to switch to these drugs if needed (Fig.13). We also detected the low level of 
resistance to NNRTI-associated ARVs. K103 mutation was the most common, occurred in 
approximately 26.4% children resulting in resistance to EFV and NVP. Though our cohort had no 
child on NVP, except for seven who were sdNVP exposed, resistance to NVP could have been due to 
the fact that EFV and NVP drugs from the same class. The majority of the children were still 















Figure 13: Overall Genotypic susceptibility scores stratified by drugs in use at the time of therapy failure 
where 0 indicates drug resistance (blue), 0.5 indicates intermediate drug resistance (red), and 1 indicates 
susceptible (green). Panel A: represents GSS scores inferred from Sanger sequencing while Panel B: 






































































5.1 General comments  
Transmission of HIV among children has been significantly reduced with pMTCT intervention yet 
nearly 200 000 HIV-infected children are currently receiving ART in South Africa
3
.   Since 2004 
when South Africa effectively initiated ART rollout to HIV-infected individuals, ART scale-up has 
increased rapidly and this intervention has greatly reduced HIV-1 morbidity and mortality among 
adults and children alike
6
. However, the development of DRMs including minority drug resistance 
mutations in HIV-1 infected patients is inevitable and will compromise the benefits of ART to reduce 
HIV-1 related morbidity and mortality
59
. This is particularly devastating for children who have to 
remain on ART for significantly longer than adults.  Therefore, WHO recommends that in the process 
of ART scale-up developing countries should establish a national surveillance program for HIV drug 
resistance monitoring
4
. The Southern African HIV Clinicians Society guidelines recommend drug 
resistance genotyping for all patients experiencing virologic failure, following attempts to improve 
adherence and other psycho-social challenges
17
. Resistance genotyping at ART initiation and during 
therapy can guide the selection of optimal drug regimens to suppress viral replication and promote 
successful management of HIV-1 infection
86
.   
 
The Sanger sequencing is currently used for resistance genotyping
4
 ; however, studies have shown that 
this method is only sensitive when DRMs are occurring at a frequency of  >20% within the total 
patient's viral population
15
. With advancement in technology there has been a development of a 
number of sensitive assays which can detect DRMs occurring at <20% of the viral population termed 
minority DRMs
15
.  The presence of minority drug resistance mutations has been shown to compromise 
long-term treatment success as early as within the first year of ART initiation
14, 15, 20-22, 28, 55, 87-95
.  It is 
for this reason that a deeper understanding of the impact of minority drug resistance mutations on 
ART failure particularly in resource-limited setting needs to be gained.  We sought to contribute to 
this understanding by profiling and investigating the prevalence of minority DRMs occurring at <20% 
frequencies in children failing ART in a rural KwaZulu-Natal setting.Our findings highlights that deep 
sequencing does provide useful information regarding drug resistance that can be used in ART 
management programs particularly with its abilities to detect minority DRMs which were not detected 
by traditional Sanger sequencing.  
 
5.2 Results discussion 
This retrospective study that included 34 children ≤15 years of age on ART for at least a year and 
experiencing virologic failure was to the best of our knowledge, the first to be conducted in a rural 
KwaZulu-Natal cohort in South Africa. The prevalence of DRMs was measured by both Sanger 
sequencing with its ability to detect DRMS present in >20% of the total viral population and NGS able 
to detect DRMs present at frequencies down to <1% of the viral population. Among these children, 21 
were initiated on an NNRTI-based regimen (classified as NNRTI-based regimen group) and 13 were 
initiated on PI regimen (classified as PI-based regimen group). Although our sample size was small, 
this study is unique because it is the first study to our knowledge (1) to compare patients failing first 
line NNRTI and PI-based regimens at minority levels, (2) use two high technology platforms to 
interrogate DRMs, (3) investigate the prevalence of minority DRMs at virologic failure among 
children in a rural setting, the depth of information detected would indicate that this technology may 
be a useful tool in patient management. All patients in this cohort were from the Hlabisa sub-district, a 
resource-limited setting where health services are decentralized into 17 clinics in the Hlabisa 









Among 34 patients, 29 (85.2%) had at least one DRM. This suggests that these children were failing 
due to the emergence of resistance, and a high prevalence of resistance has been previously reported 
by Pillay et al
81
. While five patients were susceptible, the detection of DRMs could be a tool to 
distinguish children failing therapy due to non-adherence as opposed to those failing due to resistance 
in a timely manner such that patients do not remain on failing regimen for extended periods of time. 
M184V was the most prevalent mutation detected in our cohort. Mutations at the M184 location are 
usually the first to appear when patients are exposed to 3TC
19, 97
. NNRTI-associated K103N was the 
second most prevalent mutation detected and is associated with nevirapine and efavirenz use. We 
detected 14 (41%) children having a mixture of NNRTI/NRTI mutations. The prevalence of these two 
mutations occurring simultaneously results in complex resistance patterns such as cross-resistance to 
multiple drugs within the same class or over other drug classes
81
. In resource-limited settings such as 
South Africa, first and second line regimens consist of 2 NRTI (as a backbone) with either an NNRTI 
or a PI 
6
. The emergence of mutations to these classes is of the great concern especially in cases of 





A total of 9 (26.4%) children harboured at least one TAM , five of whom had multiple (>3) TAMs. 
Only two children from the PI-based regimen group had TAMs compared to eight from the NNRTI-
based regimen group. Children in the NNRTI-based group remained on a failing regimen for 
significantly (p<0.01) longer than patients on a PI-based regimen (median = 8.6 years versus 3.5 years 
respectively). Given that prolonged failure on first-line regimens leads to the accumulation of drug 
resistance mutations and subsequently therapy failure
18
. However, it is concerning to know that even 
after viral load monitoring, patients remained on failing regimens for prolonged periods without any 
intervention ultimately resulting in the accumulation of DRMs. Others have noted similar patterns of 
complex DRMs in children in both urban 
18, 21, 27, 28, 38
 and rural settings 
81
. Unfortunately, the presence 
of TAMs is associated with the high-level and cross-resistance to ddl and TDF 
18, 30, 81, 88
, while 
multiple TAMs results in high-level resistance to NRTIs (e.g. AZT and d4T) as well as intermediate 
resistance to ddI, ABC and TDF 
18, 30, 81, 88
. Equally disturbing is that the accumulation of TAMs results 
in diminished susceptibility to multiple NRTI thus causing broad cross-resistance to the NRTI drug 




Mutations detected by NGS were reliable if the coverage was above 100, which increased the 
confidence of calling mutations occurring at <20% frequency, given that studies have reported that 
NGS is prone to homopolymer reading error resulting in false positive detection of different DRMs 
especially minority DRMs
99
. We chose NGS because of its abilities to provide a snapshot of the entire 
spectrum of resistance DRMs within the viral population in a single run
67
, provides a high throughput 
of data and at a comparable; if not, reduced cost
79
. In our cohort Sanger sequencing detected the 
majority of anticipated mutations associated with ARTs currently in use. However, we noted that the 
use of NGS platform revealed a number of DRMs missed by Sanger sequencing. Furthermore, we 
identified three children who were found to be susceptible by Sanger sequencing to be harbouring at 
least one DRM when NGS was used.  This confirms the higher sensitivity of NGS over Sanger 










NGS was able to detect at least one minority DRMs in eleven children (32.3%) that were not detected 
by Sanger sequencing. Minority DRMs were detected at frequencies between 10.2% and 20.9%. 
Whether these minority DRMs have any clinical impact on patients is still a point of debate
15
. Through 
studies conducted both on adults
20
 and children 
14, 15, 20, 22, 55, 87-95
, we now know that minority DRMs 
predispose patients to virologic failure. Studies conducted on children have shown that minority 
DRMs detected at baseline regardless of the history of sdNVP predisposed those children to therapy 
failure
15
. Indeed, minority mutations detected at baseline were shown to increase into major mutations 
over time on ART resulting in therapy failure
15
.   This demonstrates the critical role of accurate DRM 




We noticed the lesser prevalence of DRMs in PI-based regimen group, in agreement with other studies
 
39, 40
. In our study children were still susceptible on a PI regimen compared to those on an NNRTI-
based regimen who had a greater number of both major and accessory mutations as well as TAMs. 
The lack of PI mutations may be a result of the high genetic barrier of LPV/r or the presence of drug 
resistance mutations outside of the protease region e.g. the HIV gag or env genes. Studies are 
emerging showing that the presence of mutations in Gag or the cytoplasmic tail of Env could affect 
drug resistance to PIs
87, 100
, even in the absence of major DRMs within the pol gene. PI-based 
regimens due to their robust genetic barrier appear to be ideal as a first-line option in children given 
that they will have to remain on ART for longer periods compared to adults. Whole genome 
sequencing of HIV using NGS will; therefore, allow researchers and clinicians to identify patients that 
are in virologic failure due to mutation in genes other than the presence of DRMs in the pol gene.  
 
We found a study done in the UK
64
 on when to switch to second-line regimen after elevated VL results 
in children enrolled on either NNRTI or PI- based regimens. They noted that if these children were 
kept on failing regimens, there was an additional 10% NRTI DRMs (predominantly TAMs and 
M184V) in the delayed switching of NNRTI-based regimen group that was not seen in the PI-based 
regimen group
87
. Therefore, in our cohort this scenario is further explaining low prevalence of DRM 
among PI-based regimen group though on virologic failure when compared to a high prevalence of 
resistance detected among NNRTI based-regimen group. Using NGS, we found that 25(73.5 %) 
children harboured accessory mutations, of these 11.7 % did not have any major DRMs. Accessory 
mutations are polymorphisms that alone do not result in drug resistance and only contribute in the 
presence of major mutations to resistance
56
. The role of these mutations at a minority level to 
treatment failure requires further investigation.  
 
The use of NVP in mothers and infants as part of pMTCT strategies could select for DRMs resulting 
in treatment failure when on first-line regimens containing NNRTI.  Of the seven children who were 
previously exposed to sdNVP, three from PI group had at least one NNRTI-associated mutation.  
YI88C and V179D were observed occurring as minority variants in two children, while another child 
harboured only the V179D mutation. We speculate that these DRMs were persisted as minority 
variants following sdNVP exposure in two of the three children. We noted that children previously 
exposed to NVP reacted better to PI-based first line regimens. In contrast to other studies, we noted 
that the presence of Y181C was not common in our cohort, although a number of studies from the 
Sub-Saharan Africa region conducted on children reported predominantly Y181C and K103N in their 
cohorts
15, 94, 101-103
. Three studies from South Africa
15, 101, 102
 and one from Tanzania
103
 and multi-centre 
study
94
 investigated the occurrence of the major mutations K103N and Y181C among children 
previously exposed to sdNVP, and found that the presence of these mutations was associated with 
virologic failure.  In resource-limited settings such as these countries, this poses a serious problem, 
since NVP forms a major part of the first-line regimens and pMTCT protocols. Moreover, the 
emergence of NVP resistance can result in cross-resistance to EFV a key component of first-line 




The emergence of drug resistance progresses fast when drugs are not maintained within an optimal 
therapeutic range 
86
. There are several challenges in paediatric management that complicate adherence 
to their regimens, among them include medication being administered by grandparents and the 
inherent problems associated with an older caregiver, the palatability of liquid formulations and 
inability to swallow ARV drugs and  storage conditions of medications that do not heat stable
86
. It is; 
therefore, critical that patients adhere to their ART regimens for adequate suppression of the HIV-1.  
 
5.3 Limitations 
Our study has some strength and limitations, strengths include that this study was conducted in a rural 
KwaZulu-Natal cohort having one of the highest burdens in South Africa
18, 81
. Previous investigations 
of resistance patterns in children have primarily focused on urban setting and none to our knowledge; 
was done using NGS technology on patients from a rural setting.  Unravelling the complex patterns of 
drug-resistance mutations occurring at majority and minority frequencies in variable settings will add 
a critical depth to successful, long-term management of children on ART. A limitation such as since 
this was a retrospective study patients who could have been included were not due to that sample was 
depleted. Limitations of our study included a small sample size and a single time point which made it 
difficult to well establish a good understanding on persistence of minority DRMs among these 
children. Despite a small sample size, we were able to establish that minority mutations are prevalent 
among patients at virologic failure and that DRMs are missed using traditional Sanger sequencing 
where patients may be incorrectly identified as susceptible to their regimens.  Further studies to look at 
minority variants in larger cohorts at different time points are required for the better understanding of 
the clinical impact by minority variants in order to inform national policies. We propose that our study 
be expanded to a larger cohort and include multiple time points in order to fully interrogate the impact 
of the patterns of minority drug resistance mutation and their persistence on treatment failure among 
children on NRTI- and PI-based ART regimens. It was noted that very few patients had PI-associated 
DRMs, we detected three using Sanger sequencing and six using NGS platform. However, these 
patients were experiencing virologic failure; therefore, it is likely that we could have missed mutations 
outside the pol region. We also propose that further studies should be done to interrogate gag and gag-
























5.4 Conclusion  
When faced with a need of ART for a lifetime among children it is crucial that the use of ART should 
be maximized due to the limited ART options in South Africa. Given that the emergence of DRMs 
leads directly to therapy failure among patients on ART. Accurate identification of DRMs is pivotal 
and we found that NGS appears to be more specific, sensitive and efficient as compared with Sanger 
sequencing
79
. Its abilities could present a management tool in patient’s harbouring DRMs at an 
affordable cost
79
. In contrast, we have shown as others have, that traditional Sanger sequencing will 




In addition we detected a high prevalence of resistance mutations by both technologies suggesting that 
patients remained in virologic failure for extended periods of time. This highlights the need for timely 
identification of patients failing ART and the implementation of early interventions, be it drug 
switches or effective, reinforced, adherence counselling with appropriate follow-up
19, 99
. The PI-based 
regimens were more effective than NNRTI-based regiments most likely due to PI’s higher genetic 
barrier. However, PIs are sometimes not well-tolerated by children and there remains a lack of syrup 
formulations for children.  It is; therefore, likely that these children were failing due to reasons other 
than the presence of DRMs as shown by patients with susceptible virus determined by both methods.  
 
Although we had a small sample size, it was noted that children previously exposed to sdNVP 
responded well on ART particularly if they were initiated on a PI-based regimen. In agreement with a 
number of previous studies
14, 15, 20, 22, 26, 56, 88-95
. We noted that Sanger sequencing missed a number of 
mutations and even classified children (n=3) as susceptible but who harboured mutations detected 
using NGS. The prevalence of minority DRMs was high (32.3%) in our cohort; however, it must be 
noted that this is a snapshot of a single time-point.  A larger study which would interrogate the clinical 
impact of minority DRMs at baseline, therapy failure and a follow-up sample will inform us on a 
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